OBJECTIVE: @entity369 - @entity3488 (AVP) might be a potent vasopressor agent in @entity2922 -resistant @entity1457 . However, its use remains experimental because of considerations about deleterious effects on the heart. We report on the effects of continuous AVP-infusion on cardiac performance, biomarkers of @entity741 , and systemic hemodynamics in @entity2922 -resistant @entity1457 . DESIGN: Retrospective study. SETTING: Twenty-one-bed general and surgical intensive care unit. @entity1 : Forty-one @entity1 with @entity2922 -resistant @entity1457 . INTERVENTIONS: Continuous infusion of AVP. MEASUREMENTS AND RESULTS: Heart rate (HR), heart rhythm, mean arterial pressure (MAP), central venous pressure, mean pulmonary arterial pressure, cardiac index (CI), @entity64 volume index (SVI), left @entity64 work index (LVSWI), systemic vascular resistance (SVR) as well as @entity7604 and @entity1063 requirements were collected before and 1, 4, 12, 24, and 48 h after start of @entity1831 infusion. @entity908 kinase MB and troponin-I serum concentrations were measured daily. During AVP administration we observed a significant decrease in HR (-14.8%), @entity7604 (-17.5%), and @entity1063 requirements (-54.9%) as well as biomarkers of @entity299 and a significant increase in LVSWI (+46.2%), MAP (+41.8%) and SVR (+60%). CI and SVI remained unchanged. Forty-five percent of postoperative new-onset @entity591 ( @entity591 ) converted into sinus rhythm during AVP infusion. CONCLUSIONS: AVP was devoid of adverse effects on the heart in these @entity1 with @entity2922 -resistant @entity1457 . The significant reduction in HR, vasopressor, and inotropic support suggest a substantial improvement in myocardial performance. These findings are supported by a significant decrease of cardiac enzymes and cardioversion of @entity591 into sinus rhythm in 45.5% of @entity1 with new-onset @entity591 .

Cardiac performance during XXXX infusion in @entity1457 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1831 :: ('CHEBI:34543', 'Chemical') :: ['AVP'] @entity64 :: ('MESH:D020521', 'Disease') :: ['ventricular stroke', 'stroke'] @entity1457 :: ('MESH:D012769', 'Disease') :: ['postcardiotomy shock'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['Creatine'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac ischemia'] @entity591 :: ('MESH:D013610', 'Disease') :: ['TA', 'tachyarrhythmias'] @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine'] @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia'] @entity7604 :: ('MESH:D020105', 'Chemical') :: ['milrinone'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity369 :: ('CHEBI:29016', 'Chemical') :: ['Arginine'] @entity3488 :: ('551', 'Gene') :: ['vasopressin']
@entity3488 :: (551,Gene) :: ['vasopressin']
